Surendralal Karsanbhai Elected to Merck Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BMO Capital Reiterates Outperform Rating on Merck (MRK)
November 25, 2024 8:01 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $136.00 price target on Merck (NYSE: MRK).
The analyst comments "ZENITH trial has been stopped early due to overwhelming efficacy of sotatercept in functional class III/IV PAH patients. Following the compelling... More
